0001209191-20-030498.txt : 20200519
0001209191-20-030498.hdr.sgml : 20200519
20200519163524
ACCESSION NUMBER: 0001209191-20-030498
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200515
FILED AS OF DATE: 20200519
DATE AS OF CHANGE: 20200519
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kewalramani Reshma
CENTRAL INDEX KEY: 0001735944
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20894174
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS, INC.
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-15
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001735944
Kewalramani Reshma
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
1
0
0
CEO & President
Common Stock
2020-05-15
4
S
0
2
274.37
D
26723
D
Common Stock
2020-05-15
4
S
0
6
276.40
D
26717
D
Common Stock
2020-05-15
4
S
0
7
279.70
D
26710
D
Common Stock
2020-05-15
4
S
0
9
280.47
D
26701
D
Common Stock
2020-05-15
4
S
0
6
281.74
D
26695
D
Common Stock
2020-05-15
4
S
0
4
282.74
D
26691
D
Common Stock
2020-05-15
4
S
0
10
283.76
D
26681
D
Common Stock
2020-05-15
4
S
0
27
286.07
D
26654
D
Common Stock
2020-05-15
4
S
0
19
287.63
D
26635
D
Common Stock
2020-05-15
4
S
0
9
288.37
D
26626
D
Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $274.37 (range $274.03 to $274.71).
Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $276.40 (range $275.85 to $276.75).
Open market sales reported on this line occurred at a weighted average price of $279.70 (range $279.13 to $280.06).
Open market sales reported on this line occurred at a weighted average price of $280.47 (range $280.16 to $280.73).
Open market sales reported on this line occurred at a weighted average price of $281.74 (range $281.24 to $282.23).
Open market sales reported on this line occurred at a weighted average price of $282.74 (range $282.46 to $283.35).
Open market sales reported on this line occurred at a weighted average price of $286.07 (range $285.72 to $286.63).
Open market sales reported on this line occurred at a weighted average price of $287.63 (range $287.18 to $288.10).
Open market sales reported on this line occurred at a weighted average price of $288.37 (range $288.23 to $288.47).
/s/ Sabrina Yohai, Attorney-in-Fact
2020-05-19